Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 26, 2013
Context: The filing discloses a private offering of debt securities and provides management commentary regarding the use of proceeds to fund commercialization and achieve cash flow break-even.
Key Financial Metrics and Capital Structure
- Debt Offering: $75.0 million aggregate principal amount of 7.50% Convertible Senior Secured Notes due 2019.
- Over-Allotment Option: Initial purchasers granted a 30-day option to purchase up to an additional $15.0 million.
- Closing Date: Expected May 3, 2013, subject to customary conditions.
- Use of Proceeds:
- $21.0 million to repay and terminate the existing secured credit facility.
- $24.0 million to fund commercialization of Oxtellar XR and Trokendi XR.
- $19.0 million for pipeline development and general corporate purposes.
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, or cash flow figures for the period.
Material Changes and Strategic Outlook
The primary material change is the execution of a new financing strategy to replace the existing secured credit facility with convertible notes. Management states this financing is designed to take the Company through cash flow break-even. The proceeds will specifically support the commercialization of approved and tentatively approved drugs.
Management Commentary and Risks
- Regulation FD Disclosure: The filing includes an April 2013 Management Presentation to lenders, which is furnished but not deemed "filed" for Section 18 liability purposes.
- Strategic Goal: The capital raise is explicitly intended to fund operations until the company reaches cash flow break-even.
- Risks: The closing of the offering is subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing of the $75.0 million Convertible Notes offering on or around May 3, 2013.
- Confirm the full repayment and termination of the prior secured credit facility.
- Review the attached Exhibit 99.1 (April 2013 Management Presentation) for detailed financial projections and cash burn rates not included in this summary.
- Monitor the exercise of the $15.0 million over-allotment option by initial purchasers.